Hindustan Bio Sciences Ltd
₹
None%
- close price
About
Incorporated in 2000, Hindustan Biosciences Limited is engaged in the manufacturing and sale of pharmaceutical products.
Key Points
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Operating Profit |
OPM % |
Interest |
Depreciation |
Profit before tax |
Tax % |
EPS in Rs |
Raw PDF |
Profit & Loss
Figures in Rs. Crores
Operating Profit |
OPM % |
Interest |
Depreciation |
Profit before tax |
Tax % |
EPS in Rs |
Dividend Payout % |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Figures in Rs. Crores
Equity Capital |
Reserves |
Total Liabilities |
CWIP |
Investments |
Total Assets |
Cash Flows
Figures in Rs. Crores
Net Cash Flow |
Ratios
Figures in Rs. Crores
Debtor Days |
Inventory Days |
Days Payable |
Cash Conversion Cycle |
Working Capital Days |
ROCE % |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Management
23 Apr - Appointed Devanshu Ravinder Dange as Company Secretary and Compliance Officer effective April 23, 2025.
-
Appointment of Company Secretary and Compliance Officer
23 Apr - Appointed Devanshu Ravinder Dange as Company Secretary and Compliance Officer effective April 23, 2025.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On Wednesday, April 23, 2025 - Appointment Of Mr. Devanshu Ravinder Dange As Company Secretary And Compliance Officer.
23 Apr - Appointed Devanshu Ravinder Dange as Company Secretary and Compliance Officer effective April 23, 2025.
-
Non-Applicability Of Criteria Of Large Corporate - Initial Disclosure
18 Apr - Company not classified as large corporate under SEBI circular.
-
Reg. 40(10) PCS Certificate For The Year Ended 31-03-2025
18 Apr - Submission of SEBI Regulation 40(9) compliance certificate for FY25.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Portfolio:[1]
a) Tablets
b) Capsules
c) Eye/Ear/Nasal Drops
d) Dry and Liquid Injectables
e) Liquid/Dry Syrups
f) Pre-Filled Syringes
g) Non Sterile/Sterile Ointments